<DOC>
	<DOC>NCT00997984</DOC>
	<brief_summary>The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.</brief_summary>
	<brief_title>Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>612 years old ADHD diagnosis ADHDRSIV minimum score of 28 CGIS score &gt; or = 4 Current, controlled or uncontrolled, comorbid psychiatric diagnosis Condition or illness which represent inappropriate risk to subject Known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems, exerciserelated cardiac events, or clinically significant bradycardia; orthostatic hypotension or controlled or uncontrolled hypertension Use of prohibited medication that have CNS effects or affect cognitive performance History of alcohol or substance abuse within 6 months Current use of medication that affect BP or heart rate Significantly overweight Weight of less than 55 lbs Known allergy to SPD503 Abnormal urine drug and alcohol screen</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ADHD</keyword>
</DOC>